Lysine392, a K63-linked ubiquitination site in NEMO, mediates inflammatory osteoclastogenesis and osteolysis

Journal of Orthopaedic Research

Volumn 30, Issue 4, 2012, Pages 554-560

  Alhawagri, Muhammad ^a   Yamanaka, Yasuhiro ^b   Ballard, Dean ^c   Oltz, Eugene ^a   Abu Amer, Yousef ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

NEMO; osteolysis; polymethylmethacrylate; polyubiquitination

Indexed keywords

I KAPPA B; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYSINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; POLY(METHYL METHACRYLATE); STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE MATRIX; CONTROLLED STUDY; GENE MUTATION; INFLAMMATION; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROSTHESIS MATERIAL; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; UBIQUITINATION;

ANIMALS; BONE RESORPTION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GERM-LINE MUTATION; I-KAPPA B PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LYSINE; MICE; MICE, MUTANT STRAINS; MUTAGENESIS, SITE-DIRECTED; OSTEITIS; OSTEOCLASTS; OSTEOLYSIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; POLYMETHYL METHACRYLATE; PROSTHESIS FAILURE; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 84857033023     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.21555     Document Type: Article

References (36)

1. Schwarz EM, O'Keefe RJ, Looney RJ,. 2004. Bone implant interface, osteolysis and potential therapies. J Musculoskelet Neuronal Interact 4: 390-392. (Pubitemid 40124875)
2. Abu-Amer Y,. 2003. Mechanisms of inflammatory mediators in bone loss diseases. In:, Rosier RN, Evans CH, editors. Molecular biology in orthopedics. Rosemont, IL: AAOS. 229-239.
3. Neale SD, Athanasou NA,. 1999. Cytokine receptor profile of arthroplasty macrophages foreign body giant cells and mature osteoclasts. Acta Orthop Scand 70: 452-458.
4. Ren W, Wu B, Peng X, et al. 2006. Implant wear induces inflammation, but not osteoclastic bone resorption, in RANK(-/-) mice. J Orthop Res 24: 1575-1586. (Pubitemid 44203289)
5. Sabokbar A, Itonaga I, Sun SG, et al. 2005. Arthroplasty membrane-derived fibroblasts directly induce osteoclast formation and osteolysis in aseptic loosening. J Orthop Res 23: 511-519. (Pubitemid 40631320)
6. Xu J, Wu HF, Ang ES, et al. 2009. NF-κB modulators in osteolytic bone diseases. Cytokine Growth Factor Rev 20: 7-17.
7. Teitelbaum SL,. 2006. Osteoclasts; culprits in inflammatory osteolysis. Arthritis Res Ther 8: 201.
8. Khosla S,. 2001. Minireview: the OPG/RANKL/RANK system. Endocrinology 142: 5050-5055. (Pubitemid 33131929)
9. Abu-Amer Y,. 2005. Advances in osteoclast differentiation and function. Curr Drug Targets Immune Endocr Metabol Disord 5: 347-355. (Pubitemid 41131712)
10. Abu-Amer Y, Darwech I, Clohisy JC,. 2007. Aseptic loosening of total joint replacements: mechanisms underlying osteolysis and potential therapies. Arthritis Res Ther 9 (Suppl 1): S6.
11. Boyce BF, Li P, Yao Z, et al. 2005. TNF-alpha and pathologic bone resorption. Keio J Med 54: 127-131.
12. Hallab NJ, Anderson S, Stafford T, et al. 2005. Lymphocyte responses in patients with total hip arthroplasty. J Orthop Res 23: 384-391. (Pubitemid 40287865)
13. Ritchlin CT, Schwarz EM, O'Keefe RJ, et al. 2004. RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis. J Musculoskelet Neuronal Interact 4: 276-284. (Pubitemid 39504355)
14. Wei S, Siegal GP,. 2008. Mechanisms modulating inflammatory osteolysis: a review with insights into therapeutic targets. Pathol Res Pract 204: 695-706.
15. Abbas S, Clohisy JC, Abu-Amer Y,. 2003. Mitogen-activated protein (MAP) kinases mediate PMMA-induction of osteoclasts. J Orthop Res 21: 1041-1048. (Pubitemid 37322386)
16. Yamanaka Y, Abu-Amer Y, Faccio R, et al. 2006. Map kinase c-JUN N-terminal kinase mediates PMMA induction of osteoclasts. J Orthop Res 24: 1349-1357. (Pubitemid 44083250)
17. Lee SE, Woo KM, Kim SY, et al. 2002. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone 30: 71-77. (Pubitemid 34044303)
18. Abu-Amer Y, Darwech I, Otero J,. 2008. Role of the NF-kappaB axis in immune modulation of osteoclasts and bone loss. Autoimmunity 41: 204-211. (Pubitemid 351454990)
19. Hayden MS, Ghosh S,. 2004. Signaling to NF-kappaB. Genes Dev 18: 2195-2224.
20. Hayden MS, Ghosh S,. 2008. Shared Principles in NF-[kappa]B Signaling. Cell 132: 344-362.
21. Dai S, Hirayama T, Abbas S, et al. 2004. The IκB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J Biol Chem 279: 37219-37222. (Pubitemid 39195425)
22. May MJ, D'Acquisto F, Madge LA, et al. 2000. Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 289: 1550-1554.
23. Jimi E, Aoki K, Saito H, et al. 2004. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 10: 617-624. (Pubitemid 38796853)
24. 3 (NEMO) protein in health and disease. J Cell Mol Med 14: 2404-2414.
25. Arimoto KI, Funami K, Saeki Y, et al. 2010. Polyubiquitin conjugation to NEMO by triparite motif protein 23 (TRIM23) is critical in antiviral defense. Proc Natl Acad Sci USA 107: 15856-15861.
26. Cordier F, Grubisha O, Traincard F, et al. 2009. The zinc finger of NEMO is a functional ubiquitin-binding domain. J Biol Chem 284: 2902-2907.
27. Karin M, Greten FR,. 2005. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5: 749-759. (Pubitemid 41400849)
28. Karin M, Yamamoto Y, Wang M,. 2004. The IKK NF-kB system: a treasure trove for drug development. Nat Rev 3: 17-26. (Pubitemid 38088695)
29. Clohisy JC, Yamanaka Y, Faccio R, et al. 2006. Inhibition of IKK activation, through sequestering NEMO, blocks PMMA-induced osteoclastogenesis and calvarial inflammatory osteolysis. J Orthop Res 24: 1358-1365. (Pubitemid 44083251)
30. Dai S, Hirayama T, Abbas S, et al. 2004. The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J Biol Chem 279: 37219-37222. (Pubitemid 39195425)
31. Ni C-Y, Wu Z-H, Florence WC, et al. 2008. Cutting Edge: K63-linked polyubiquitination of NEMO modulates TLR signaling and inflammation in vivo. J Immunol 180: 7107-7111.
32. Clohisy J, Frazier E, Hirayama T, et al. 2003. RANKL is an essential cytokine mediator of PMMA particle-induced osteoclastogenesis. J Orthop Res 21: 202-212. (Pubitemid 36322538)
33. Clohisy J, Hirayama T, Frazier E, et al. 2004. NF-kB signaing blockade abolishes implant particle-induced osteoclastogenesis. J Orthop Res 22: 13-20. (Pubitemid 38035440)
34. Chen ZJ,. 2005. Ubiquitin signalling in the NF-kB pathway. Nat Cell Biol 7: 758-765.
35. Burns KA, Martinon F,. 2004. Inflammatory diseases: is ubiquitinated NEMO at the hub? Curr Biol 14: R1040-R1042. (Pubitemid 40033345)
36. Maitra R, Clement CC, Scharf B, et al. 2009. Endosomal damage and TLR2 mediated inflammasome activation by alkane particles in the generation of aseptic osteolysis. Mol Immunol 47: 175-184.